Advertisement
Screener

60 DEGREES PHARMACEUTICALS, INC. (SXTP) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.9 / 5 stars · 18/31 Roast Me

60 DEGREES PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

60 DEGREES PHARMACEUTICALS, INC. (SXTP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-14

  • 60 DEGREES PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
  • 60 DEGREES PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-09-30 was 0.00%.
  • 60 DEGREES PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • 60 DEGREES PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • 60 DEGREES PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend RateShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 1 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2025-12-310.00%
10-K · filed 2026-03-30
2025-09-300.00%
10-Q · filed 2025-11-13
2025-06-300.00%
10-Q · filed 2026-08-14
2025-03-310.00%
10-Q · filed 2026-05-15
2024-12-310.00%
10-K · filed 2026-03-30
2024-09-300.00%
10-Q · filed 2025-11-13
0.00%
10-Q · filed 2025-11-13
2024-01-310.00%
10-Q · filed 2024-08-14
2023-12-310.00%
10-K · filed 2025-03-27
2023-09-300.00%
10-Q · filed 2024-11-14
2023-06-300.00%
10-Q · filed 2023-08-25
2023-05-310.00%
10-Q · filed 2023-08-25
2022-12-310.00%
10-Q · filed 2023-08-25
2022-05-310.00%
10-Q · filed 2023-08-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
REVELATION BIOSCIENCES, INC. (REVB)United States$0.004B
HCW Biologics Inc. (HCWB)United States$0.004B-6.15
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Onconetix, Inc. (ONCO)United States$0.004B
Aptevo Therapeutics Inc. (APVO)United States$0.003B
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
Sunshine Biopharma Inc. (SBFM)$0.003B
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24